Trial of Secondary Prevention With Atenolol After Transient Ischemic Attack or Nondisabling Ischemic Stroke
The Dutch TIA Trial Study Group
Background and Purpose: /3-Blockers prevent vascular events in patients after myocardial infarction and lower blood pressure, the main risk factor for stroke. Hence, we assessed the effects of atenolol on the occurrence of death from vascular causes, stroke, or myocardial infarction and on blood pressure in patients after a transient ischemic attack or nondisabling ischemic stroke.
Methods: In a double-blind, placebo-controlled randomized clinical trial we studied the occurrence of the outcome event death from vascular causes, nonfatal stroke, or nonfatal myocardial infarction and the outcome event fatal or nonfatal stroke as well as blood pressure on follow-up. A total of 1,473 aspirin-treated patients with transient ischemic attack or nondisabling ischemic stroke were randomized to 50 mg atenolol daily or placebo. The mean follow-up was 2.6 years.
Results: Patients on atenolol had a risk of 97/732 (13.3%) for the combined outcome event versus a risk of 95/741 (12.8%) for those on placebo (adjusted hazard ratio, 1.00; 95% confidence interval, 0.76-1.33). The adjusted hazard ratio for fatal or nonfatal stroke was 0.82 (95% confidence interval, 0.57-1.19). More patients on ^-blocker (153) reported adverse effects than on placebo (103). At the first follow-up visit after randomization (median at 4 months) systolic blood pressure in the atenolol group had dropped by 8.0 mm Hg compared with 2.2 mm Hg in the placebo group (difference, 5.8 mm Hg; 95% confidence interval, 2.9-8.6 mm Hg). For diastolic blood pressure this difference was 2.9 mm Hg (95% confidence interval, 1.
5-4.4 mm Hg).
Conclusions: Our data neither confirm nor rule out that atenolol prevents important vascular events in patients after transient ischemic attack or nondisabling ischemic stroke, given the modest effect on blood pressure, the restrictions in patient selection, and the limited number of patient-years. T he annual risk of death from vascular causes, nonfatal stroke, or nonfatal myocardial infarction in patients suffering a transient ischemic attack (TIA) or nondisabling ischemic stroke is 7-12% without preventive treatment. [1] [2] [3] [4] [5] Aspirin is known to reduce this risk by 20-25%. ischemic stroke is the use of /3-blocking drugs. The rationale for their use is at least twofold. First, myocardial infarction is the leading cause of death in patients with cerebral ischemia, 24 -9 and trials of secondary prevention of vascular events with /S-blockers in patients with myocardial infarction show a decreased incidence of vascular events. 10 Second, trials on the blood pressure-lowering effect of /3-blockers show a reduced risk of stroke. 11 At this moment it is not clear whether these two effects are also beneficial for patients after TIA or nondisabling ischemic stroke.
The Dutch TIA Trial was a double-blind and placebocontrolled randomized clinical trial with two treatment comparisons in patients with a TIA or nondisabling ischemic stroke. In the /3-blocker study we analyzed whether 50 mg/day atenolol reduced the occurrence of death from vascular causes, stroke, or myocardial infarction in comparison with placebo. In the aspirin study we investigated whether a low dose (30 mg/day) of aspirin was more effective than a medium dose (283 mg/day) in the prevention of these same outcome events. The detailed methods of the study and the results of the aspirin study have been described elsewhere 12
Subjects and Methods Patients who were seen by a neurologist in one of the 56 collaborating centers (seven fewer than in the aspirin study) between February 28, 1986, and March 3, 1989, were eligible for the trial if they had had a TIA (symptoms persisting less than 24 hours) or nondisabling ischemic stroke (symptoms persisting more than 24 hours) less than 3 months before. Patients with a stroke had to be independent in most of their daily activities (score on the modified Rankin Scale 1415 of grade 3 or less). Excluded were patients with cerebral ischemia from identifiable causes other than arterial thrombosis or arterial embolism and patients with a contraindication against or a strict indication for a /3-blocker. The study protocol had been approved by the institutional review boards of the participating hospitals.
To obtain the neurological symptoms as reliably as possible a checklist in plain language was used. 16 Apart from the specific history we recorded demographic data, vascular risk indicators (including blood pressure and history of vascular events), drug treatment, selected data from laboratory tests, the cardiothoracic ratio as calculated from the chest roentgenogram, and findings from a standard 12-lead electrocardiogram. 13 Computed tomography (CT) of the brain was mandatory in all patients except in those with transient monocular blindness.
A total of 1,473 patients were enrolled, of whom 1,454 also participated in the aspirin study; 1,677 other patients were entered into the aspirin study only. Balance between treatment allocation within hospitals was achieved by the use of random permuted blocks; blinded randomization codes were distributed by telephone. Atenolol was supplied as 50 mg tablets to be taken once a day; placebo tablets had an identical appearance and taste. No run-in period was included in the study design.
Every 4 months all patients were seen by their neurologist or, if the patient could not attend the hospital clinic, by their general practitioner irrespective of whether they still used the trial medication. The occurrence of TIAs, outcome events (see below), vascular diseases, vascular surgery, changes in medication, or possible adverse effects was recorded at each visit, and the blood pressure was measured. For diastolic blood pressure phase V was taken during a single measurement in the sitting position by means of a mercury manometer. All patients had their last follow-up visit between March 1, 1990, and June 30, 1990; the mean duration of follow-up was 32 months, with a minimum of 12 and a maximum of 52 months. No patient was lost to follow-up.
The primary outcome event was the combined occurrence of death from vascular causes, nonfatal stroke, or nonfatal myocardial infarction, whichever occurred first. Secondary outcome events were death from all causes, death from vascular causes, and the occurrence of death from vascular causes plus nonfatal stroke. Tertiary outcome events were fatal stroke, the combination of fatal and nonfatal stroke, cardiac death, and the combination of cardiac death and nonfatal myocardial infarction. No separate analyses of nonfatal events were planned. For the definition of elements of the primary, secondary, and tertiary outcome events we refer to a previous publication. 13 All outcome events were independently classified by at least three members of the Auditing Committee for Outcome Events, without knowledge of treatment allocation. All possible adverse effects as reported by the patients were recorded; the physician inquired about such effects in a general fashion.
A second type of analysis compared the blood pressure during follow-up with that at randomization. Mean blood pressures according to allocated treatment were calculated at 4-month intervals corresponding to the planned frequency of follow-up visits. Because actual visits often did not coincide exactly with this scheme, we used the measurements obtained within intervals of 4 months around the scheduled visits.
The size of the Dutch TIA Trial was determined primarily by the number of patients required for the aspirin study. 12 For the atenolol study it was assumed that the rate of death from vascular causes or nonfatal The major aim of data analysis was to compare the incidence of the primary outcome event between treatment groups in the two studies. Kaplan-Meier curves were used for graphic comparison. 17 The occurrence of outcome events was compared in terms of the hazard ratio (HR), i.e., the ratio between the risk of the outcome event per unit of time for patients randomly assigned to study treatment and the risk for those randomly assigned to conventional treatment. HRs were obtained by use of the Cox proportional hazards model 18 and adjusted for baseline incomparabilities (EGRET statistical package 19 ). The precision of the HR estimates was described by means of 95% confidence intervals obtained from the Cox model. Subgroup analyses (see "Results") were planned in advance. The primary data analysis was based on the intention-totreat principle; whether or not medication was taken, patients were analyzed in their originally allocated treatment group until the last follow-up visit. In addition we performed on-treatment analyses, in which we included patients only for the time the trial medication was taken and in which we counted only those outcome events occurring before the 28th day after discontinuation of the trial medication. Patients inappropriately entered into the study with diseases other than cerebral ischemia (« = 9) were included in the intention-to-treat analysis but excluded from the on-treatment analysis.
Results
In Table 1 baseline characteristics of the 1,473 patients are presented according to allocated treatment. One third of the patients were women; there was a slight excess of males and of patients more than 65 years old in the atenolol group. The qualifying event for the study was a TIA in one third and a nondisabling ischemic stroke in two thirds of the patients. Three quarters of the patients were randomized within 1 month after the qualifying event. Of the patients allocated to atenolol 358 (48.9%) received 30 mg aspirin compared with 357 (48.2%) of those allocated to placebo.
After 1 year, 81% of the surviving patients were still taking their trial medication. After 3 years, this number was 64% in the atenolol group and 68% in the placebo group (Table 2) ; this difference was statistically significant (/?=0.03, log-rank test). Adverse effects and other medical reasons (for instance, angina, hypertension, or intermittent claudication) were the most common reasons for premature stopping of the trial medication; twice as many patients on atenolol stopped because of an adverse effect as patients on placebo. Figure 1 presents Kaplan-Meier curves for the primary outcome event. Table 3 shows the occurrence of first outcome events according to allocated treatment based on intention-to-treat analysis. The age-and sexadjusted HR (1.00) was slightly smaller than its crude Table 2 . HR, hazard ratio; CI, confidence interval; MI, myocardial infarction; adjusted, for age and sex. *Patient-years for primary outcome event; patient-years for other outcome events are slightly higher. fWhichever occurred first.
analogue because the slight imbalance of randomization with regard to age and sex was to the disadvantage of the atenolol group. Adjustment for other baseline characteristics had no influence on the HR estimates. Sixtyone percent of all deaths were of vascular origin (43% cardiac, 16% cerebral, and 2% other). The crude HR for the combination of fatal and nonfatal stroke was 0.84; that for cardiac death or nonfatal myocardial infarction was 1.15. Crude HRs calculated according to an on-treatment analysis hardly differed from those calculated according to the intention-to-treat analysis; for the primary outcome event of the study (death from vascular causes, nonfatal stroke, or nonfatal myocardial infarction) the HR with the on-treatment analysis was 1.05.
Adverse reactions of any kind were significantly more frequent in the patients on atenolol than in those on placebo (Table 4) .
Planned subgroup analyses for the primary outcome event according to sex, age, history of hypertension, presence of ischemic heart disease, and current cigarette smoking showed no significant differences between HRs of the subgroups. In particular, no difference was observed between HRs for patients on low-dose and those on medium-dose aspirin (HRs 1.10 and 0.98, respectively; p=0.69) and current smokers and nonsmokers (HRs 1.10 and 0.97, respectively;/?=0.67). Figure 2 shows the average systolic and diastolic blood pressures during follow-up according to allocated treatment (intention-to-treat analysis). At the first fol- Some adverse effects are expected pharmacological effects causing only signs and no symptoms, but these led to discontinuation of trial drug. Some patients had several adverse effects. 
Graphs of mean levels of systolic (SBP, top panel) and diastolic (DBP, lower panel) blood pressure by allocated treatment. Intention-to-treat analysis.
low-up visit after randomization (median at 4 months), systolic blood pressure in the atenolol group had dropped by 8.0 mm Hg on average and in the placebo group by 2.2 mm Hg (difference, 5.8 mm Hg; 95% confidence interval, 2.9-8.6 mm Hg). For diastolic blood pressure the difference was 2.9 mm Hg (95% confidence interval, 1.5-4.4 mm Hg). In the on-treatment analysis these differences were somewhat larger (6.9 and 3.5 mm Hg, respectively). The effect of atenolol on blood pressure did not differ between the two aspirin groups (30 or 283 mg/day).
Discussion We could not demonstrate an effect of 50 mg atenolol on the primary outcome event (age-and sex-adjusted risk reduction, 0%; 95% confidence interval, -33% to 24%) nor on any of the secondary outcome events. However, the incidence of the tertiary outcome event fatal or nonfatal stroke was nonsignificantly lower in the patients allocated to 50 mg atenolol (age-and sexadjusted risk reduction, 18%; 95% confidence interval, -19% to 43%), whereas that of cardiac death or nonfatal myocardial infarction (also a tertiary outcome event) was somewhat higher under atenolol treatment (age-and sex-adjusted risk reduction, -12%; 95% confidence interval, -72% to 27%). In the on-treatment analysis we arrived at the same conclusions.
The lack of a clear effect of atenolol on prevention of the combined outcome event of death from vascular causes, nonfatal stroke, and nonfatal myocardial infarction in patients after a TIA or nondisabling ischemic stroke seems to be at variance with the results of secondary prevention trials in patients with myocardial infarction. 10 There may be at least three explanations for our findings. First, and perhaps most important, we may have missed the expected beneficial effect of atenolol because of the limited number of patients admitted to the /3-blocker study; the 95% confidence interval indicates that the findings of the study are still compatible with a 24% risk reduction. Second, the patients who entered the /3-blocker part of our study were at lower risk of a vascular event than those who were ineligible because there was a possible source of embolism in the heart, because they were already using /3-blockers, or because there were contraindications against /3-blockers such as diabetes or congestive heart disease. In addition, only about one quarter of the patients in the atenolol study had a history of hypertension compared with more than 50% of the patients enrolled only in the aspirin study. In quantitative terms, the patients included in the aspirin study but excluded from the atenolol study had an annual risk of 7.0% for the combined outcome event compared with 5.2% of the patients in the atenolol study. The Beta-Blocker Pooling Project Research Group reported a higher benefit, in absolute terms, of /3-blockers in high-risk patients than in those with a low risk. 21 Third, our result may have depended on the type of /3-blocker or its dosage. The pharmacological explanation of the beneficial effect of /3-blockers after myocardial infarction remains unclear. Antiarrhythmic, antihypertensive, and antiplatelet effects have all been invoked. 10 /3-Blockers without intrinsic sympathetic activity (such as atenolol) are more effective than those with such activity. 10 With regard to the dosage, 50 mg atenolol has been shown previously to have substantial antihypertensive effects 22 ; we did not choose a higher dose to avoid adverse effects of a drug being used for prevention. A dose of 100 mg atenolol, however, may be more effective. 23 Furthermore, the excess of adverse effects and the lowering of blood pressure in atenolol-treated patients confirms that this dosage did indeed have a biological effect. On the other hand, the many reported side effects in the placebo group reflect the alertness of many neurologists in detecting these because many were unfamiliar with the use of /3-blockers. The excess of adverse effects in the atenolol-treated group was probably caused to some extent by cardiovascular signs, not symptoms. The adverse effects never consisted of major, life-threatening complications.
The finding that the risk for fatal or nonfatal stroke was (nonsignificantly) reduced by atenolol is consistent with the overviews on blood pressure and the primary prevention of stroke and coronary heart disease. 11, 24 The combined data from 14 randomized trials of antihypertensive drugs showed a reduction of stroke incidence by 42% during an average follow-up of 5 years, while on average diastolic blood pressure was lowered by 6 mm Hg. 11 Data from observational studies indicated that the lower the diastolic blood pressure, the lower the stroke incidence. 24 Extrapolation of these overviews to our trial would result in a more modest reduction of the stroke incidence than 42% because of a shorter follow-up (2.6 versus 5 years) and a smaller effect on diastolic blood pressure (2-3 versus 5-6 mm Hg), and with this proviso they are quite in agree-merit with the actual reduction of 18%. Moreover, in the recently published Medical Research Council trial of treatment of hypertension in the elderly 50 mg atenolol daily also reduced the incidence of (fatal or nonfatal) stroke by 18% (95% confidence interval, -12% to 40%). 25 In a secondary prevention trial among 452 stroke survivors a combined preparation of 0.5 mg deserpidine and 5.0 mg methyclothiazide reduced the incidence of stroke or cardiovascular outcome events by 24% (95% confidence interval, -5% to 46%), while diastolic blood pressure was lowered by approximately 12 mm Hg. 26 We did not find any harmful effects of atenolol, particularly no increase in the rate of cerebral infarction, an adverse effect of antihypertensive treatment that has been postulated as a possible result of diminished cerebral perfusion. 27 At any rate, prophylactic treatment with /3-blockers in patients with TIA or nondisabling ischemic stroke is safe. However, before atenolol can be used in the secondary prevention of vascular events after a cerebral ischemic event, a beneficial effect should be demonstrated in samples even larger than in our study (at least 10,000 person-years) or in patients who are at high risk for a cardiovascular event.
